Because the taste of nicotine gum has impeded compliance with dosing recommendations, nicotine gum with improved taste (mint, orange) was developed and marketed. Prior to marketing, the Food and Drug Administration (FDA) required a rigorous abuse liability assessment to examine whether enhanced palatability of nicotine gum would increase its abuse liability. Subjective, physiological, and psychomotor effects of mint flavor and original nicotine gum were tested in adult smokers (22-55 years old); a group of younger subjects (18-21 years old) was also included to allow for assessment of abuse liability in young adults specifically. Amphetamine and confectionery gum served as positive controls for abuse liability and palatability. Subjects rated palatability of mint gum higher than original nicotine gum, but substantially lower than confectionery gum. Palatability decreased with increasing dose of nicotine. Neither original nor mint gum increased ratings of traditional abuse liability predictors [Good Effect, Like Effect, Morphine-Benzedrine Group (MBG) scales of Addiction Research Center Inventory (ARCI)], while amphetamine increased ratings of all these measures. Both flavors of nicotine gum decreased craving during 2 h of abstinence. These effects were more pronounced in the adult group and mint gum was more effective than original gum. Younger subjects reported fewer withdrawal symptoms and lower ratings for drug effects and flavor. Improved flavor of nicotine gum does not increase abuse liability, but may be associated with enhanced craving reduction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0091-3057(02)00723-2 | DOI Listing |
Am J Sports Med
January 2025
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Background: Selective androgen receptor modulators (SARMs) are small-molecule compounds that exert agonist and antagonist effects on androgen receptors in a tissue-specific fashion. Because of their performance-enhancing implications, SARMs are increasingly abused by athletes. To date, SARMs have no Food and Drug Administration approved use, and recent case reports associate the use of SARMs with deleterious effects such as drug-induced liver injury, myocarditis, and tendon rupture.
View Article and Find Full Text PDFCNS Drugs
January 2025
Cognitive and Clinical Neuroimaging Core, McLean Hospital, McLean Imaging Center, Belmont, MA, USA.
The relationship between cannabis use and mental health is complex, as studies often report seemingly contradictory findings regarding whether cannabis use results in more positive or negative treatment outcomes. With an increasing number of individuals using cannabis for both recreational (i.e.
View Article and Find Full Text PDFAm J Psychiatry
January 2025
Department of Psychiatry (McIntyre, Mansur, Rosenblat) and Department of Pharmacology and Toxicology (McIntyre, Mansur, Rosenblat), University of Toronto, Toronto; Brain and Cognition Discovery Foundation, Toronto (Kwan, Teopiz); Faculty of Medicine, University of Ottawa, Ottawa (Kwan); Champalimaud Research and Clinical Center, Champalimaud Foundation, Lisbon (Oliveira-Maia); NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisbon (Oliveira-Maia); Department of Psychiatry and Behavioral Sciences, University of South Carolina School of Medicine, Greenville (Maletic); Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford (Suppes); Department of Psychiatry, University of California, San Diego (Stahl).
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder. Preliminary evidence also supports efficacy in other psychiatric disorders (e.
View Article and Find Full Text PDFDrug Alcohol Depend
January 2025
Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, USA; Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA.
Introduction: Electronic nicotine delivery system (ENDS) product standards for nicotine flux (nicotine emitted/second), combined with limiting puff duration, could control nicotine dose and support ENDS regulations. We assessed behavioral and subjective abuse liability indices for ENDS varying in nicotine flux with fixed puff duration among people who smoke.
Methods: This within-subjects study included 32 adults who smoked cigarettes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!